Grace Therapeutics, Inc. (GRCE) Form 10-K Annual Reports
Grace Therapeutics, Inc. (GRCE) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: GRCE
CIK: 1444192
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 03/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
KPMG LLP
Auditor SinceSince 3/31/2024 12:00:00 AM
Lead Engagement PartnerRyan Breen
Audit LocationPhiladelphia, Pennsylvania, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-10-16 | 2026-10-14 | 4 | 0001493152-26-047473 | View SEC Doc Filr Page |
| 4 | 2026-10-13 | 2026-10-08 | 4 | 0001493152-26-046899 | View SEC Doc Filr Page |
| 4 | 2026-10-05 | 2026-10-01 | 4 | 0001493152-26-045809 | View SEC Doc Filr Page |
| 4 | 2026-10-01 | 2026-09-29 | 4 | 0001493152-26-045358 | View SEC Doc Filr Page |
| 4/A | 2026-10-01 | 2026-09-21 | 4/A | 0001493152-26-045347 | View SEC Doc Filr Page |
| 4 | 2026-09-23 | 2026-09-21 | 4 | 0001493152-26-043996 | View SEC Doc Filr Page |
| 4 | 2026-09-21 | 2026-09-17 | FORM 4 | 0001140361-26-037246 | View SEC Doc Filr Page |
| 4 | 2026-09-21 | 2026-09-17 | FORM 4 | 0001140361-26-037245 | View SEC Doc Filr Page |
| 4 | 2026-09-21 | 2026-09-17 | FORM 4 | 0001140361-26-037239 | View SEC Doc Filr Page |
| 4 | 2026-09-21 | 2026-09-17 | FORM 4 | 0001140361-26-037237 | View SEC Doc Filr Page |
| 8-K | 2026-09-18 | 2026-09-17 | 8-K | 0001140361-26-037114 | View SEC Doc Filr Page |
| 4 | 2026-09-10 | 2026-09-08 | 4 | 0001493152-26-042152 | View SEC Doc Filr Page |
| 4 | 2026-09-10 | 2026-09-09 | FORM 4 | 0001140361-26-036125 | View SEC Doc Filr Page |
| 4 | 2026-09-01 | 2026-08-28 | FORM 4 | 0001140361-26-035318 | View SEC Doc Filr Page |
| 4 | 2026-09-01 | 2026-08-28 | FORM 4 | 0001140361-26-035319 | View SEC Doc Filr Page |
| 4 | 2026-09-01 | 2026-08-28 | FORM 4 | 0001140361-26-035317 | View SEC Doc Filr Page |
| 4 | 2026-09-01 | 2026-08-28 | FORM 4 | 0001140361-26-035316 | View SEC Doc Filr Page |
| EFFECT | 2026-08-31 | — | EFFECT Filing | 9999999995-26-002839 | View SEC Doc Filr Page |
| S-3 | 2026-08-24 | — | S-3 | 0001140361-26-034189 | View SEC Doc Filr Page |
| 4 | 2026-08-19 | 2026-08-14 | 4 | 0001493152-26-039124 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001104659-26-097338 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001104659-26-097290 | View SEC Doc Filr Page |
| 8-K | 2026-08-13 | 2026-08-13 | 8-K | 0001140361-26-032644 | View SEC Doc Filr Page |
| 10-Q | 2026-08-13 | 2026-06-30 | 10-Q | 0001140361-26-032632 | View SEC Doc Filr Page |
| D | 2026-08-11 | — | D Filing | 0001123292-26-001084 | View SEC Doc Filr Page |